Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
AMNEAL PHARMACEUTICALS, INC. (AMRX) Return on Tangible Equity data is not available for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$3.02B |
|
$72.06M |
|
$1.91B |
|
$1.11B |
|
$2.62B |
|
$394.10M |
|
$-254.89M |
|
$139.21M |
|
$139.21M |
|
$127.93M |
|
$127.93M |
|
$127.93M |
|
$127.93M |
|
$394.10M |
|
$640.10M |
|
313.37M |
|
324.81M |
|
$0.23 |
|
$0.22 |
|
| Balance Sheet Financials | |
$1.91B |
|
$442.95M |
|
$1.77B |
|
$3.68B |
|
$881.63M |
|
$2.57B |
|
$2.87B |
|
$3.75B |
|
-- |
|
$-1.23B |
|
$-71.33M |
|
-- |
|
| Cash Flow Statement Financials | |
$339.99M |
|
$-112.26M |
|
$-31.53M |
|
$118.42M |
|
$312.94M |
|
$194.52M |
|
$31.95M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Tangible Equity |
-- |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|